FEB 15, 2017 09:00 AM PST
WEBINAR: Advances in Parathyroid Hormone Testing
SPONSORED BY: DiaSorin
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
14 32 4686

Speakers:
  • Professor of Clinical Chemistry at the University of Liege and Head of the Department of Clinical Chemistry at CHU de Liege
    Biography
      Etienne Cavalier was born in Liege, Belgium in 1971. He received his Master in Pharmaceutical Sciences in 1994, his Advanced Master in Clinical Biology in 1999 and his PhD in Pharmaceutical and Biomedical Sciences in 2010 from the University of Liege. Etienne Cavalier is now Professor of Clinical Chemistry at the University of Liege and Head of the Department of Clinical Chemistry at the CHU de Liege. His main research topics are linked with the phosphocalcic metabolism, renal function, frailty and sarcopenia. Etienne Cavalier has published over 200 papers, 6 book chapters and has an h-index of 25. Professor Cavalier also serves on the Clinica Chimica ACTA's editorial board.

    Abstract:

    DATE:  February 15, 2017
    TIME:  9:00am PT, noon ET

    Parathyroid hormone (PTH) is an 84 amino acid that plays a key role in phosphocalcic metabolism. Its measurement is essential to diagnose and treat primary hyperparathyroidism and to evaluate chronic kidney disease-mineral and bone disorders (CKD-MBD).  PTH determination is not an easy task, because of the many similar fragments that circulate in our blood. Among these fragments are a group commonly called (7-84) PTH, which are truncated in the amino-terminal part of the peptide. These fragments are quite low in normal healthy subjects; they accumulate in patients with chronic kidney diseases (CKD) and can be up to 50% of the (1-84) PTH in hemodialyzed patients (HD).

    Clinical laboratories are often using “intact” PTH assays.  These assays detect the (1-84) peptide and the (7-84) PTH fragments. Because these fragments are recognized differently by the various assays, the values obtained are often very different between “intact” kits. 3rd generation PTH assays, are specific for the (1-84) PTH and do not cross-react with the (7-84) fragments, resulting in less variability.  Up to now, 3rd generation PTH assays have not demonstrated any clinical benefit over intact PTH assays.  However, PTH standardization can be achieved only with 3rd generation and it will be impossible to standardize assays using the intact PTH kits, because of variable cross-reactivities to fragments.

    It is important to carefully select the “normal” subjects to establish reference ranges that allow the proper interpretation of the patient’s PTH results. These “normals” should not have secondary hyperparathyroidism and should have eGFR, 25(OH)D, calcium and phosphorus levels within a normal range. Unfortunately, manufacturers have not judiciously selected their “normals”, leading to falsely elevated PTH reference ranges. Using correctly established PTH reference ranges will assist physicians in correctly classifying HD patients in the appropriate bone turnover category.

    Learning objectives: 

    • To understand the 2nd and 3rd generation PTH assays and their cross-reactivity to different circulating forms
    • To understand the importance of good reference range establishment for PTH
    • To understand the importance of PTH standardization
    • To get up-to-date information regarding PTH stability 

    Show Resources
    Loading Comments...